公开(公告)号：US09745323B2

公开(公告)日：2017-08-29

申请号：US14418342

申请日：2013-07-30

Applicant: KYOTO UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  KINOPHARMA, INC.

Inventor： Masatoshi Hagiwara ,  Hiroshi Onogi ,  Isao Kii ,  Takamitsu Hosoya ,  Yuto Sumida

IPC: C07D513/04 ,  C07D405/06 ,  C07D417/06

CPC classification number: C07D513/04 ,  C07D405/06 ,  C07D417/06

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition. One or more embodiments disclose a compound expressed by the following general formula (I) or (II) or a pharmaceutically acceptable salt of the compound:

公开(公告)号：US20150133467A1

公开(公告)日：2015-05-14

申请号：US14406101

申请日：2013-06-06

Applicant: KYOTO UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY

Inventor： Masatoshi Hagiwara ,  lsao Kii ,  Takamitsu Hosoya ,  Yuto Sumida ,  Suguru Yoshida

IPC: A61K31/496

CPC classification number: A61K31/496 ,  A61K31/426 ,  A61K31/437 ,  A61K31/495 ,  A61K31/695 ,  C07D213/83 ,  C07D277/20 ,  C07D277/36 ,  C07D471/04

Abstract: Provided is a screening method with which it is possible to determine the cause of a decrease or an increase in the amount of a target protein that is expressed by a cell. One or a plurality of embodiments include: conducting cultivation that includes bringing an assay cell into contact with a test substance, and measuring a relative amount (A) of the target protein in relation to an internal standard; conducting cultivation in which an assay cell is not brought into contact with a test substance, and measuring a relative amount (B) in relation to an internal standard; comparing the relative amount (A) and the relative amount (B); and, based on the comparison, selecting a candidate substance that induces instability and/or stability in the target protein. The assay cell is a cell that is able to express mRNA of the target protein and mRNA of the internal standard protein under the identical regulation of gene expression, or a cell having a means for expressing mRNA of the target protein and mRNA of the internal standard protein under the identical regulation of gene expression.

Abstract translation: 提供了可以确定由细胞表达的靶蛋白的量的减少或增加的原因的筛选方法。 一个或多个实施方案包括：进行培养，其包括使测定细胞与测试物质接触，并测量靶蛋白相对于内标的相对量（A）; 进行培养，其中测定细胞不与测试物质接触，并测量相对于内标的相对量（B）; 比较相对量（A）和相对量（B）; 并且基于比较，选择诱导靶蛋白的不稳定性和/或稳定性的候选物质。 测定细胞是能够在基因表达相同调节下表达内标蛋白的靶蛋白和mRNA的mRNA的细胞，或具有​​表达靶蛋白的mRNA和内标的mRNA的方法的细胞 蛋白质在相同的基因表达调控下。

公开(公告)号：US11318126B2

公开(公告)日：2022-05-03

申请号：US16329063

申请日：2017-08-31

Applicant: KYOTO UNIVERSITY

Inventor： Masatoshi Hagiwara ,  Akiko Kobayashi ,  Takamitsu Hosoya ,  Suguru Yoshida ,  Yuto Sumida

IPC: A61K31/47 ,  A61K31/443 ,  A61P43/00 ,  A61P25/24 ,  A61K31/4709 ,  A61P25/16 ,  A61K45/00 ,  A61P25/14 ,  A61P25/02 ,  A61K31/4439 ,  A61K31/4725 ,  A61P25/28 ,  A61P25/00 ,  A61K31/416 ,  C12N5/0793

Abstract: Provided is a composition for activating neurogenesis, use of the composition, and a method for preventing, improving, inhibiting the development of, and/or treating a disease or the like of the central nervous system and or the peripheral nervous system using the composition. A composition for activating neurogenesis contains, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing, improving, inhibiting the development of, and/or treating a disease of the central nervous system and/or the peripheral nervous system, or for improving, inhibiting the development of, and/or treating a functional disorder of the central nervous system and/or the peripheral nervous system, the composition containing, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10017524B2

公开(公告)日：2018-07-10

申请号：US15660364

申请日：2017-07-26

Applicant: KYOTO UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  KINOPHARMA, INC.

Inventor： Masatoshi Hagiwara ,  Hiroshi Onogi ,  Isao Kii ,  Takamitsu Hosoya ,  Yuto Sumida

IPC: C07D405/06 ,  C07D417/06 ,  C07D513/04

CPC classification number: C07D513/04 ,  C07D405/06 ,  C07D417/06

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition. One or more embodiments disclose a compound expressed by the following general formula (I) or (II) or a pharmaceutically acceptable salt of the compound:

公开(公告)号：US20150225421A1

公开(公告)日：2015-08-13

申请号：US14418342

申请日：2013-07-30

Applicant: KYOTO UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  KINOPHARMA, INC.

Inventor： Masatoshi Hagiwara ,  Hiroshi Onogi ,  Isao Kii ,  Takamitsu Hosoya ,  Yuto Sumida

IPC: C07D513/04 ,  C07D405/06 ,  C07D417/06

CPC classification number: C07D513/04 ,  C07D405/06 ,  C07D417/06

Abstract: The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition. One or more embodiments disclose a compound expressed by the following general formula (I) or (II) or a pharmaceutically acceptable salt of the compound:

Abstract translation: 本发明提供了用于神经心理学障碍或恶性肿瘤的化合物和药物组合物，该化合物和药物组合物的用途，或用于预防，改善，抑制发展和/或治疗神经心理障碍或恶性肿瘤的方法， 使用该化合物和药物组合物。 一个或多个实施方案公开了由以下通式（I）或（II）表示的化合物或其化合物的药学上可接受的盐：